Acquisitions (Tables)

6 Months Ended

Jun. 30, 2011

Taligen Therapeutics, Inc [Member]

Acquisition-Related Costs

	Three months ended	Six months ended
	June 30,	June 30,
	2011	2011
Separately-identifiable employee costs	$                                 -	$                   6,597
Professional fees	41	2,729
Changes in fair value of contingent consideration	666	750
	$                             707	$               10,076

Reconciliation Of Upfront Payments To Total Purchase Price

	Taligen
Upfront payment in accordance with agreement	$   111,773
Separately-identifiable employee costs	(6,259)
Total consideration transferred	$ 105,514
Estimated fair value of contingent consideration	11,634
Total purchase price	$ 117,148

Purchase Price Allocation To Assets Acquired And Liabilities Assumed

	Taligen
Cash and cash equivalents	$       2,678
Purchased technology	5,000
In-process research and development	59,500
Other assets	555
Assets acquired	67,733
Deferred tax liability (net)	(9,567)
Other liabilities assumed	(1,084)
Liabilities assumed	(10,651)
Goodwill	60,066
Net assets acquired	$ 117,148

Pro Forma Financial Information Of Combined Results Of Operations

	Three months ended	Six months ended
	June 30,	June 30,
	2010	2011	2010
Revenues	$         125,834	$         351,825	$         243,412
Net income	18,477	60,469	36,714
Earnings per common share
Basic	$               0.10	$               0.33	$               0.21
Diluted	$               0.10	$               0.32	$               0.20

Orphatec Pharmaceuticals GmbH [Member]

Acquisition-Related Costs

	Three months ended	Six months ended
	June 30,	June 30,
	2011	2011
Professional fees	$                              214	$                      721
Changes in fair value of contingent consideration	79	131
	$                             293	$                    852

Reconciliation Of Upfront Payments To Total Purchase Price

	Orphatec
Upfront payments in accordance with agreement	$       3,050
Estimated fair value of contingent consideration	5,086
Total purchase price	$      8,136

Purchase Price Allocation To Assets Acquired And Liabilities Assumed

	Orphatec
In-process research & development	$       8,050
Other noncurrent assets	73
Assets acquired	8,123
Goodwill	13
Net assets acquired	$      8,136